Viewing Study NCT03059251


Ignite Creation Date: 2025-12-24 @ 11:45 PM
Ignite Modification Date: 2026-02-24 @ 2:31 PM
Study NCT ID: NCT03059251
Status: COMPLETED
Last Update Posted: 2020-04-17
First Post: 2017-02-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina
Sponsor: Hoffmann-La Roche
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Lymphocytic Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CLL, obinutuzumab, treatment View